CA3236670A1 - Deuterated functionalized derivatives of .alpha.-alanine, in particular for the treatment of neurological diseases - Google Patents
Deuterated functionalized derivatives of .alpha.-alanine, in particular for the treatment of neurological diseases Download PDFInfo
- Publication number
- CA3236670A1 CA3236670A1 CA3236670A CA3236670A CA3236670A1 CA 3236670 A1 CA3236670 A1 CA 3236670A1 CA 3236670 A CA3236670 A CA 3236670A CA 3236670 A CA3236670 A CA 3236670A CA 3236670 A1 CA3236670 A1 CA 3236670A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- mmol
- propanamide
- dioxopyrrolidin
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLP.439639 | 2021-11-24 | ||
| PL439639A PL244897B1 (pl) | 2021-11-24 | 2021-11-24 | Deuterowane funkcjonalizowane pochodne α-alaniny, zwłaszcza do leczenia chorób neurologicznych |
| PCT/PL2022/050083 WO2023096512A1 (en) | 2021-11-24 | 2022-11-24 | DEUTERATED FUNCTIONALIZED DERIVATIVES OF α-ALANINE, IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3236670A1 true CA3236670A1 (en) | 2023-06-01 |
Family
ID=84980841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3236670A Pending CA3236670A1 (en) | 2021-11-24 | 2022-11-24 | Deuterated functionalized derivatives of .alpha.-alanine, in particular for the treatment of neurological diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250042848A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4436954A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024543135A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240110038A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118302410A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022395821A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236670A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005981A (cg-RX-API-DMAC7.html) |
| PL (1) | PL244897B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023096512A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260100334A (ko) * | 2023-10-20 | 2026-06-29 | 알타이 테라퓨틱스, 인크. | 신경근육 장애 등의 치료를 위한 dux4 억제제로서의 n-페닐-3-(2,5-디옥소피롤리딘-1-일)프로판아미드 유도체 및 유사 화합물 |
| PL450241A1 (pl) * | 2024-11-12 | 2026-05-18 | Uniwersytet Jagielloński | Pozytywny allosteryczny modulator (PAM) transportera EAAT2/GLT-1 glutaminianu do stosowania w leczeniu lub zapobieganiu świądu |
| WO2026150001A1 (en) | 2025-01-09 | 2026-07-16 | Iqure Pharma Inc. | Positive allosteric modulator (pam) of the eaat2/glt-1 glutamate transporter for use in the treatment or prevention of dravet syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL244071B1 (pl) * | 2019-01-07 | 2023-11-27 | Univ Jagiellonski | Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym |
| PL240297B1 (pl) * | 2019-04-16 | 2022-03-14 | Univ Jagiellonski | Modyfikowane pochodne aminokwasowe do leczenia chorób o podłożu neurologicznym oraz wybranych zaburzeń psychiatrycznych |
-
2021
- 2021-11-24 PL PL439639A patent/PL244897B1/pl unknown
-
2022
- 2022-11-24 CN CN202280077941.8A patent/CN118302410A/zh active Pending
- 2022-11-24 US US18/711,775 patent/US20250042848A1/en active Pending
- 2022-11-24 CA CA3236670A patent/CA3236670A1/en active Pending
- 2022-11-24 WO PCT/PL2022/050083 patent/WO2023096512A1/en not_active Ceased
- 2022-11-24 KR KR1020247020140A patent/KR20240110038A/ko active Pending
- 2022-11-24 AU AU2022395821A patent/AU2022395821A1/en active Pending
- 2022-11-24 EP EP22843893.3A patent/EP4436954A1/en active Pending
- 2022-11-24 MX MX2024005981A patent/MX2024005981A/es unknown
- 2022-11-24 JP JP2024531057A patent/JP2024543135A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL244897B1 (pl) | 2024-03-25 |
| AU2022395821A1 (en) | 2024-06-06 |
| JP2024543135A (ja) | 2024-11-19 |
| US20250042848A1 (en) | 2025-02-06 |
| WO2023096512A1 (en) | 2023-06-01 |
| CN118302410A (zh) | 2024-07-05 |
| PL439639A1 (pl) | 2023-05-29 |
| MX2024005981A (es) | 2024-06-28 |
| EP4436954A1 (en) | 2024-10-02 |
| KR20240110038A (ko) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250042848A1 (en) | DEUTERATED FUNCTIONALIZED DERIVATIVES OF alpha-ALANINE, IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| OA12132A (en) | Novel esters derived from (RR,SS)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl. | |
| ES3051032T3 (en) | Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders | |
| JP2014503480A (ja) | ジュウテリウムリッチなラサギリン | |
| AU2022203369B2 (en) | Analogs of deutetrabenazine, their preparation and use | |
| RU2513856C2 (ru) | Способы получения метилового эфира 4-оксооктагидроиндол-1-карбоновой кислоты и ее производные | |
| JP6775009B2 (ja) | 3−ビシクロ[3.2.0]ヘプ−3−エン−6オンエンの鏡像異性体の分離 | |
| ES3020435T3 (en) | Water-soluble, modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders | |
| WO2016149540A1 (en) | Therapeutic compounds and formulations for intranasal delivery | |
| EP3867244B1 (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| US20150045574A1 (en) | Methods for making valerenic acid derivatives and their use | |
| JP7841757B2 (ja) | T型カルシウムチャネル調節因子及びその使用方法 | |
| EP3866854B1 (en) | 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament | |
| EP3867245B1 (en) | 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| EP4488260A1 (en) | New aminoketone compound, and preparation method therefor and use thereof | |
| US6384228B2 (en) | Method for synthesis of halopyridyl-azacyclopentane derivative and intermediate thereof | |
| WO2025064699A1 (en) | Therapeutic uses for epimers of hexahydrocannabivarin, hexahydrocannabidivarin, hexahydrocannabinol, hexahydrocannabidiol, and other hydrogenated cannabinoids | |
| JP2025523852A (ja) | セラストロール誘導体 | |
| EP1992637A1 (en) | 1-Aminocyclopentane-1,3,4- tricarboxylic acids derivatives | |
| WO2026102446A1 (en) | Calcium channel modulators and methods of using thereof | |
| HK40059626B (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| HK40059626A (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241120 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241120 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251020 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251020 |